At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 103 enrolled

Drug / intervention

Placebo +1 moredrug

Likely dose

Levodopa 100mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02560389

NCT02560389Phase 4Completed

Compare CT.gov

Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

University of Wisconsin, Madison·interventional·Posted Sep 25, 2015·Updated Jun 25, 2019

In Brief

A Phase 4 clinical trial evaluating Placebo and Levodopa for Stress Disorder, Post Traumatic. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsStress Disorder, Post Traumatic

CountriesUnited States

Collaborators--

Timeline

Phase 4CompletedFinished

20162017201820192020202120222023202420252026

First PostedSep 2015

Enrollment StartMar 2016

Primary CompletionMay 2018

TodayJul 2026

First PostedSep 25, 2015

Enrollment StartMar 1, 2016

Primary CompletionMay 1, 2018

TodayJul 2, 2026

Enrollment to primary: 2.2 yearsPosted 10.8 years ago

Interventions

Placebodrug

Sugar pill packaged to resemble levodopa

Levodopadrug

EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.